

1 May 2024

Company Announcements Office  
Australian Securities Exchange

## **Nanosonics Announces FDA Regulatory Submission for CORIS® Innovation**

Nanosonics (ASX: NAN), a leader in infection control solutions, is pleased to announce the De Novo submission of its latest innovation, CORIS®, to the U.S. Food and Drug Administration (FDA).

Following the successful completion of the Clinical In-Use Study, the FDA submission represents a significant step toward addressing one of the most critical challenges in instrument reprocessing today: the cleaning of flexible endoscopes, in particular the complex channels which are prone to biofilm build up.

“CORIS is a groundbreaking technology designed to revolutionise endoscope reprocessing. By combining cutting-edge science and engineering with practical usability, Nanosonics aims to enhance patient safety and improve healthcare outcomes. CORIS represents a significant opportunity for the organisation and the submission to the FDA marks a pivotal moment in the Company’s journey. We look forward to engaging with the FDA during the evaluation process”, said Michael Kavanagh, Nanosonics’ Chief Executive Officer and President.

During the regulatory review, Nanosonics will continue to conduct, publish, and present studies showcasing the superior cleaning outcomes achieved with the CORIS technology and progress the necessary activities required to support its commercialisation.

**Michael Kavanagh**  
**CEO / President**

This announcement has been authorised by the Board of Directors of Nanosonics.

**For more information, please contact:**  
Michael Kavanagh, CEO / President on (02) 8063 1600.